Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 217Lymphoid 176Myeloid 112Plasma cell 75Dermatologic 55Classical hematology 34Sarcoma 28Genitourinary 13Gynecologic 12Breast 10CNS 6Head & Neck 5Gastrointestinal 5Thoracic 3Other neoplasm 3Tumor-Agnostic 2Other solid neoplasm 1

Conditions

Neoplasms 2Neoplasm Metastasis 1

Interventions

Paclitaxel 26Carboplatin 25pembrolizumab 22Gemcitabine 22Nivolumab 20Cisplatin 15Bevacizumab 14Docetaxel 13Pemetrexed 12Ipilimumab 12Erlotinib Hydrochloride 12Capecitabine 12Fluorouracil 11Irinotecan 10Afatinib 10eribulin 9BI 6727 9130-nm albumin-bound paclitaxel 9Radiotherapy 8Magnetic Resonance Spectroscopy 8Leucovorin 8Everolimus 8Cyclophosphamide 8Albumin-Bound Paclitaxel 8olaparib 7Oxaliplatin 7lenvatinib 6avelumab 6Trastuzumab 6Cetuximab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × fludarabine phosphate × Tumor-Agnostic × Clear all
NCT03296137 2024-10-26

Adoptive Cell Therapy Across Cancer Diagnoses

Herlev Hospital

Phase 1/2 Completed
25 enrolled 9 charts
Tumor-Agnostic

Neoplasms

NCT00924287 2015-10-28

Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
1 enrolled 8 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡